New antibiotic from MSD

Schedule 3 - pharmacist holding out pill bottles
MSD today announced that its new antibiotic has been registered by the Therapeutic Goods Administration for the treatment of common and problematic gram-negative pathogens. The first new antibiotic registered in Australia in almost ten years for the treatment of gram-negative pathogens, ZERBAXA (ceftolozane/tazobactam) is approved for use in hospitals for the treatment of complicated intra-abdominal

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Time allows Regulation Impact Statement on codeine: PSA
Next Australia needs 'cultural shift' on antibiotics: NPS